These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26879387)

  • 1. Digoxin reduces atherosclerosis in apolipoprotein E-deficient mice.
    Shi H; Mao X; Zhong Y; Liu Y; Zhao X; Yu K; Zhu R; Wei Y; Zhu J; Sun H; Mao Y; Zeng Q
    Br J Pharmacol; 2016 May; 173(9):1517-28. PubMed ID: 26879387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting the Th17/IL-17A-related inflammatory responses with digoxin confers protection against experimental abdominal aortic aneurysm.
    Wei Z; Wang Y; Zhang K; Liao Y; Ye P; Wu J; Wang Y; Li F; Yao Y; Zhou Y; Liu J
    Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2429-38. PubMed ID: 25234817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice.
    Erbel C; Chen L; Bea F; Wangler S; Celik S; Lasitschka F; Wang Y; Böckler D; Katus HA; Dengler TJ
    J Immunol; 2009 Dec; 183(12):8167-75. PubMed ID: 20007582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergic asthma accelerates atherosclerosis dependent on Th2 and Th17 in apolipoprotein E deficient mice.
    Wang L; Gao S; Xu W; Zhao S; Zhou J; Wang N; Yuan Z
    J Mol Cell Cardiol; 2014 Jul; 72():20-7. PubMed ID: 24530901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice.
    Zhang WJ; Bird KE; McMillen TS; LeBoeuf RC; Hagen TM; Frei B
    Circulation; 2008 Jan; 117(3):421-8. PubMed ID: 18158360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice.
    Danzaki K; Matsui Y; Ikesue M; Ohta D; Ito K; Kanayama M; Kurotaki D; Morimoto J; Iwakura Y; Yagita H; Tsutsui H; Uede T
    Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):273-80. PubMed ID: 22116098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TSLPR deficiency attenuates atherosclerotic lesion development associated with the inhibition of TH17 cells and the promotion of regulator T cells in ApoE-deficient mice.
    Wu C; He S; Peng Y; Kushwaha KK; Lin J; Dong J; Wang B; Lin J; Shan S; Liu J; Huang K; Li D
    J Mol Cell Cardiol; 2014 Nov; 76():33-45. PubMed ID: 25117469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
    Guo X; Wang L; Xia X; Wang P; Li X
    Biomed Pharmacother; 2019 Jan; 109():1445-1453. PubMed ID: 30551396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Nuclear Receptor RORγ and Interleukin-17A Suppresses Neovascular Retinopathy: Involvement of Immunocompetent Microglia.
    Talia DM; Deliyanti D; Agrotis A; Wilkinson-Berka JL
    Arterioscler Thromb Vasc Biol; 2016 Jun; 36(6):1186-96. PubMed ID: 27055905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
    Wang Z; Wang S; Wang Z; Yun T; Wang C; Wang H
    Biochem Biophys Res Commun; 2017 Aug; 490(2):194-201. PubMed ID: 28601639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
    Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
    J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digoxin attenuates acute cardiac allograft rejection by antagonizing RORγt activity.
    Wu J; Zhou C; Chen W; Xie A; Li J; Wang S; Ye P; Wang W; Xia J
    Transplantation; 2013 Feb; 95(3):434-41. PubMed ID: 23296151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peperomin E (PepE) protects against high fat diet-induced atherosclerosis in Apolipoprotein E deficient (ApoE
    Yan J; Li M; Wang XD; Lu ZY; Ni XL
    Biomed Pharmacother; 2018 Sep; 105():862-869. PubMed ID: 30021379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-27 Prevents Atherosclerosis by Suppressing Lipoprotein Lipase-Induced Lipid Accumulation and Inflammatory Response in Apolipoprotein E Knockout Mice.
    Xie W; Li L; Zhang M; Cheng HP; Gong D; Lv YC; Yao F; He PP; Ouyang XP; Lan G; Liu D; Zhao ZW; Tan YL; Zheng XL; Yin WD; Tang CK
    PLoS One; 2016; 11(6):e0157085. PubMed ID: 27257686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
    Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
    Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background.
    Sontag TJ; Krishack PA; Lukens JR; Bhanvadia CV; Getz GS; Reardon CA
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):262-9. PubMed ID: 24334873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice.
    Atkinson RD; Coenen KR; Plummer MR; Gruen ML; Hasty AH
    Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E284-90. PubMed ID: 18029445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice.
    Koulis C; Chen YC; Hausding C; Ahrens I; Kyaw TS; Tay C; Allen T; Jandeleit-Dahm K; Sweet MJ; Akira S; Bobik A; Peter K; Agrotis A
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):516-25. PubMed ID: 24436372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes.
    Fougerat A; Gayral S; Gourdy P; Schambourg A; Rückle T; Schwarz MK; Rommel C; Hirsch E; Arnal JF; Salles JP; Perret B; Breton-Douillon M; Wymann MP; Laffargue M
    Circulation; 2008 Mar; 117(10):1310-7. PubMed ID: 18268153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice.
    Huang K; Li SQ; Wang WJ; Liu LS; Jiang YG; Feng PN; Wang YQ; Wang SM
    Int J Immunopathol Pharmacol; 2012; 25(2):397-406. PubMed ID: 22697071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.